Overview

Webcast ImageWebcast
ChromaDex Year End 2016 Conference Call (Replay)
03/17/17 at 1:00 p.m. ET
ChromaDex Year End 2016 Conference Call
Friday, March 17, 2017 1:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Where the power of nature meets the logic of science for the betterment of health.
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and acquire early stage, ingredient technologies that are protected by intellectual property.... More »

Stock Quote
NASDAQ - CDXC
Price$2.57
Change (%) Stock is Down 0.05 (1.91%)
Volume44,068
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
DateTitle 
03/16/17ChromaDex Reports 2016 Record Revenue as Ingredient Sales Grew 34%
Q4 Total Revenue Increased 29% and 2016 Total Revenue Increased 22% IRVINE, Calif., March 16, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today the financial results for the year ended Dec. 31, 2016. “We finished 2016 on a strong note, generating 29% year over ... 
Printer Friendly Version
03/10/17ChromaDex to Report Year End 2016 Financial Results on Thursday, March 16, 2017
Company Will Host Investor Conference Call on Friday, March 17, 2017 IRVINE, Calif., March 10, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its year end 2016 financial results on Thursday, March 16, after the close of the financial... 
Printer Friendly Version
02/23/17A Letter from the ChromaDex Chief Executive Officer
IRVINE, Calif., Feb. 23, 2017 (GLOBE NEWSWIRE) -- The following is issued on behalf of ChromaDex: Dear Fellow Shareholders: In January 2016, I issued a shareholder letter wherein I described in some detail my enthusiasm surrounding the enormous commercial opportunity we have with our patented NIAGEN® nicotinamide riboside (NR), a next-generation form of Vitamin B3 with what I believe has blockbuster potential in the emerging category of NAD+ (nicotinamide adenine dinucleotide) precursors. ... 
Printer Friendly Version
Upcoming EventsMore »

There are currently no events scheduled.

What's New
Download Documentation2016 Annual Report on Form 10K
Download Documentation2016 Q3 Quarterly Report on Form 10Q
Download DocumentationShareholder Letter
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.